Breast cancer followed by corpus cancer: Is there a higher risk for aggressive histologic subtypes?

被引:29
作者
Chan, John K.
Manuel, Michael R.
Cheung, Michael K.
Osann, Kathryn
Husain, Amreen
Teng, Nelson N.
Rao, Anjali
Carlson, Robert W.
Whittemore, Alice S.
机构
[1] Stanford Univ, Med Ctr, Div Gynecol Oncol, Dept Obstet & Gynecol,Stanford Canc Ctr, Stanford, CA 94305 USA
[2] Stanford Univ, Stanford Canc Ctr, Sch Med, Dept Med, Stanford, CA 94305 USA
[3] Univ Calif Irvine, Med Ctr, Chao Family Comprehens Canc Ctr, Div Hematol Oncol,Dept Med, Orange, CA 92868 USA
[4] Stanford Univ, Div Epidemiol, Dept Hlth Res & Policy, Stanford, CA 94305 USA
关键词
breast cancer; uterine cancer; papillary serous; sarcoma; survival;
D O I
10.1016/j.ygyno.2006.01.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Objective. To analyze corpus cancer patients with a breast cancer history for risk of developing aggressive uterine histologic types. Methods. Corpus cancer patients with a history of breast cancer were identified from the Surveillance Epidemiology and End Results database from 1988 to 2001. Demographics, clinico-pathologic, and survival data were analyzed using Kaplan-Meier and logistic regression analyses. Results. Of 52,109 women diagnosed with corpus cancer, 1922 had a history of breast cancer. Women with a history of breast cancer had a significantly higher Proportion of uterine papillary serous carcinomas (UPSC) and sarcomas compared to those without a breast cancer history (9.4% vs. 6.3% for UPSC and 10.3% vs. 8.4% for sarcoma; P < 0.001). Patients with endometrioid or sarcoma of the uterus after breast cancer had significantly worse 5-year survivals than patients without a breast cancer history (84.4% vs. 90.5%; P < 0.001 and 49.0% vs. 63.6%, P < 0.001, respectively). Older age, advanced stage, lack of surgery and radiation treatment, poor histologic types, and history of breast cancer were independent prognostic factors for poorer survival. Conclusion. In this study, the proportional incidence of UPSC and sarcoma was significantly higher in women with a breast cancer history. These findings highlight the association of breast cancer and high-risk corpus cancer subtypes. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:508 / 512
页数:5
相关论文
共 19 条
[1]
*AM CANC SOC INC, 2004, CANC FACTS FIG
[2]
[Anonymous], SEER STAT DAT INC SE
[3]
TAMOXIFEN USE IN BREAST-CANCER PATIENTS WHO SUBSEQUENTLY DEVELOP CORPUS CANCER IS NOT ASSOCIATED WITH A HIGHER INCIDENCE OF ADVERSE HISTOLOGIC FEATURES [J].
BARAKAT, RR ;
WONG, G ;
CURTIN, JP ;
VLAMIS, V ;
HOSKINS, WJ .
GYNECOLOGIC ONCOLOGY, 1994, 55 (02) :164-168
[4]
Tamoxifen therapy for breast cancer and endometrial cancer risk [J].
Bernstein, L ;
Deapen, D ;
Cerhan, JR ;
Schwartz, SM ;
Liff, J ;
McGann-Maloney, E ;
Perlman, JA ;
Ford, L .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (19) :1654-1662
[5]
Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer [J].
Curtis, RE ;
Freedman, DM ;
Sherman, ME ;
Fraumeni, JF .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (01) :70-74
[6]
ENDOMETRIAL CANCER IN TAMOXIFEN-TREATED BREAST-CANCER PATIENTS - FINDINGS FROM THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT (NSABP) B-14 [J].
FISHER, B ;
COSTANTINO, JP ;
REDMOND, CK ;
FISHER, ER ;
WICKERHAM, DL ;
CRONIN, WM ;
BOWMAN, D ;
COUTURE, J ;
DIMITROV, NV ;
EVANS, J ;
FARRAR, W ;
KAVANAH, M ;
LICKLEY, HL ;
MARGOLESE, R ;
PATERSON, AHG ;
ROBIDOUX, A ;
SHIBATA, H ;
TERZ, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (07) :527-537
[7]
FORNANDER T, 1989, LANCET, V1, P117
[8]
Association between uterine serous carcinoma and breast cancer [J].
Gehrig, PA ;
Bae-Jump, VL ;
Boggess, JF ;
Groben, PA ;
Fowler, WC ;
Van Le, L .
GYNECOLOGIC ONCOLOGY, 2004, 94 (01) :208-211
[9]
Papillary serous carcinoma of the uterus: Increased risk of subsequent or concurrent development of breast carcinoma [J].
Geisler, JP ;
Sorosky, JI ;
Duong, HL ;
Buekers, TE ;
Geisler, MJ ;
Sood, AK ;
Anderson, B ;
Buller, RE .
GYNECOLOGIC ONCOLOGY, 2001, 83 (03) :501-503
[10]
Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? [J].
Goshen, R ;
Chu, W ;
Elit, L ;
Pal, T ;
Hakimi, J ;
Ackerman, I ;
Fyles, A ;
Mitchell, M ;
Narod, SA .
GYNECOLOGIC ONCOLOGY, 2000, 79 (03) :477-481